130 results
8-K
EX-1.1
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering … as is appropriate to reflect not only the relative benefits referred to in clause (i) of this Section 7(d) but also the relative fault of the Company on the one
424B5
STRO
Sutro Biopharma Inc
2 Apr 24
Prospectus supplement for primary offering
4:58pm
, efficacy and safety profile of our product candidates, our ability to maintain and recognize the benefits of certain designations received by product … the benefits of certain designations received by product candidates, our ability to successfully leverage Fast Track Designation, the value of our holdings
8-K
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
to, the Company’s entry into the exclusive global licensing agreement with Ipsen and potential benefits of such agreement, including potential future … payments thereunder, anticipated preclinical and clinical development activities, potential benefits of luvelta and the Company’s other product
8-K
EX-99.1
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
, including, but not limited to, the Company’s entry into the exclusive global licensing agreement with Ipsen and potential benefits of such agreement … , including potential future payments thereunder, anticipated preclinical and clinical development activities, potential benefits of luvelta
8-K
EX-99.1
b7s8hc 4i
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-1.1
097lg56919rcovws
9 Feb 24
Other Events
4:27pm
424B5
iamc09y
9 Feb 24
Prospectus supplement for primary offering
4:25pm
8-K
q1f01x9ublg1
8 Jan 24
Results of Operations and Financial Condition
7:31am
8-K
EX-99.1
79ytw
8 Jan 24
Results of Operations and Financial Condition
7:31am
8-K
EX-99.1
h6nhvh8mz312my9 csl6
21 Nov 23
Departure of Directors or Certain Officers
4:05pm